Consensus AbbVie Inc. Bulgaria S.E.

Stocks

4AB

US00287Y1091

Pharmaceuticals

End-of-day quote Bulgaria S.E. 2026-03-24			5-day change	1st Jan Change
176.40 ^EUR	-11.91%		-.--%	-7.43%

09-28	AbbVie Receives U.S. FDA Approval For JUVMO For Parkinson's Disease	CI
09-28	US drugmakers turn to China for licensing deals	RE

cb1f779c816086ca1408e1b4df5.2rKMz_Ys4ZmxQMlTm4MxBO54LyQyPZC69CJGSXrr11o.94XBn4Vgt9HQOOQEzcgcT4RJYBZbVffprRQuHT-K5ze_2vqJx3Ww7uEZ8Q~ed5ce54928cbcc8a71dbed3319b5581b

Analysts' recommendations: AbbVie Inc.

09-24	Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says	MT
09-10	HSBC Adjusts Price Target on AbbVie to $315 From $300, Keeps Buy Rating	MT
09-08	BofA Securities Adjusts Price Target on AbbVie to $282 From $276	MT
08-20	Piper Sandler Adjusts Price Target on AbbVie to $303 From $298, Maintains Overweight Rating	MT
08-17	Wells Fargo Adjusts Price Target on AbbVie to $300 From $295, Keeps Overweight Rating	MT
08-13	Wolfe Upgrades AbbVie to Outperform From Peer Perform, Price Target is $300	MT
08-11	BNP Paribas Adjusts Price Target on AbbVie to $247 From $218, Maintains Neutral Rating	MT
08-05	Argus Lifts AbbVie Price Target to $270 From $250	MT
08-05	Leerink Partners Adjusts Price Target on AbbVie to $279 From $245	MT
08-04	Guggenheim Adjusts Price Target on AbbVie to $288 From $261, Maintains Buy Rating	MT
08-04	Rothschild & Co Redburn Adjusts Price Target on AbbVie to $285 From $284, Maintains Buy Rating	MT
08-03	AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says	MT
08-03	Oppenheimer Adjusts AbbVie Price Target to $258 From $244, Maintains Neutral Rating	MT
08-03	Canaccord Genuity Adjusts AbbVie Price Target to $290 From $282, Maintains Buy Rating	MT
07-31	JPMorgan Adjusts Price Target on AbbVie to $285 From $280	MT
07-28	Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating	MT
07-22	Canaccord Genuity Adjusts Price Target on AbbVie to $282 From $273, Maintains Buy Rating	MT
07-15	Citigroup Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating	MT
07-13	BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating	MT
07-13	UBS Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating	MT
07-10	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says	MT
07-10	BofA Securities Adjusts AbbVie Price Target to $276 From $234	MT
07-10	AbbVie's Q2 Results Expected to be Inline With Expectations, RBC Says	MT
07-10	RBC Raises Price Target on AbbVie to $280 From $260, Keeps Outperform Rating	MT
07-10	Wells Fargo Adjusts Price Target on AbbVie to $295 From $260	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+11.99%
	JOHNSON & JOHNSON					+2.47%
	ABBVIE INC.					+5.4%
	ROCHE HOLDING AG					+4.17%
	NOVARTIS AG					+5.45%
	ASTRAZENECA PLC					+27.21%
	AMGEN INC.					-6.12%
	GILEAD SCIENCES, INC.					+5.12%
	NOVO NORDISK A/S					+21.56%
	Average					+8.58%
	Weighted average by Cap.					+8.23%